Share this
a remote microsampling device helps monitor cardiovascular biomarkers
by Neoteryx Microsampling on Oct 9, 2019 3:02:00 AM
The California Initiative for the Advancement of Precision Medicine (CIAPM) is a national public entity formulated to ignite rational precision medicine research on popular diseases. It funded a study that applied microsampling techniques using Mitra® devices for blood sampling and remote monitoring.
The multi-method, longitudinal, prospective cohort study identified appropriate cardiovascular biomarkers and engaged 200 patients with stable ischemic heart disease (IHD).
Lifestyle choices such as smoking, poor nutrition, and physical inactivity increase the risk of IHD. This type of heart disease is the leading killer in the United States in men and women of all ethnicities. For those already diagnosed with the condition, secondary prevention is managed within clinical environments. It focuses on the control of cholesterol, blood pressure, and diabetes.
The risk calculator for atherosclerosis cardiovascular disease is one that helps predict cardiovascular events. It considers factors such as race, sex, age, blood cholesterol and pressure, smoking status, and diabetes. Such tests are only performed during hospital or clinic visits. The tests help to prevent disastrous situations, improve healthcare access, and lower resource utilization.
The objectives of the Prediction, Risk, and Evaluation of Major Adverse Cardiac Events (PRE-MACE) study included:
- Estimating the cross-sectional links between the recognized main adverse cardiovascular occurrence (MACE) intermediate biomarkers
- Discovering the longitudinal capability of remote physiological and biochemical monitoring to forecast changes in MACE intermediate biomarkers
- Determining the ability of remote monitoring and biomarkers to forecast incident MACE at starting point and after 12 months
- Conducting exploration proteomics and lipidomics aimed at increasing the potential circulating prognostic MACE biomarkers
- Measuring the cost-effectiveness or budget-friendliness of remote monitoring for latent MACE biomarkers and MACE itself
The PRE-MACE learning is aimed at evaluating feasibility regarding adherence and pilot remote monitoring with biosensors, and biomarkers. The study actively used patient-reported outcomes (PROs) to obtain continuous insight of participants in real-time situations.
The study relied on Mitra® devices for remote biochemical biomarker monitoring. The remote blood microsampling enhances longitudinal, and volumetric blood sample collection via simple finger pricks that study participants can do at home.
The Mitra device with patented VAMS® technology has an absorbent polymeric tip that uptakes blood in a fixed volume (10 µL). This precision enhances sample heterogeneity and overcomes hematocrit bias challenges that are common with dried blood spot (DBS) collection. The study used automated email reminders or push notifications to remind participants to make their scheduled blood draws.
This study is just one of the numerous smarter healthcare practices being advanced by clinicians worldwide. Microsampling allows for volunteers to participate in clinical trials remotely and for longer periods. It makes the studies more flexible and convenient for both the clinicians and the study volunteers. Microsampling could be just what your research needs to get to the next level.
Image Credits: iStock, Trajan Scientific and Medical
Share this
- Microsampling (206)
- Research, Remote Research (119)
- Venipuncture Alternative (106)
- Clinical Trials, Clinical Research (83)
- Mitra® Device (74)
- Therapeutic Drug Monitoring, TDM (51)
- Dried Blood Spot, DBS (38)
- Biomonitoring, Health, Wellness (31)
- Infectious Disease, Vaccines, COVID-19 (24)
- Blood Microsampling, Serology (22)
- Decentralized Clinical Trial (DCT) (22)
- Omics, Multi-Omics (20)
- Specimen Collection (17)
- Toxicology, Doping, Drug/Alcohol Monitoring, PEth (17)
- hemaPEN® Device (13)
- Preclinical Research, Animal Studies (12)
- Skin Microsampling, Microbiopsy (12)
- Pharmaceuticals, Drug Development (9)
- Harpera Device (5)
- Industry News, Microsampling News (5)
- Antibodies, MAbs (3)
- Company Press Release, Product Press Release (3)
- Environmental Toxins, Exposures (1)
- December 2024 (2)
- November 2024 (1)
- October 2024 (3)
- September 2024 (1)
- June 2024 (1)
- May 2024 (1)
- April 2024 (4)
- March 2024 (1)
- February 2024 (2)
- January 2024 (4)
- December 2023 (3)
- November 2023 (3)
- October 2023 (3)
- September 2023 (3)
- July 2023 (3)
- June 2023 (2)
- April 2023 (2)
- March 2023 (2)
- February 2023 (2)
- January 2023 (3)
- December 2022 (2)
- November 2022 (3)
- October 2022 (4)
- September 2022 (3)
- August 2022 (5)
- July 2022 (2)
- June 2022 (2)
- May 2022 (4)
- April 2022 (3)
- March 2022 (3)
- February 2022 (4)
- January 2022 (5)
- December 2021 (3)
- November 2021 (5)
- October 2021 (3)
- September 2021 (3)
- August 2021 (4)
- July 2021 (4)
- June 2021 (4)
- May 2021 (4)
- April 2021 (3)
- March 2021 (5)
- February 2021 (4)
- January 2021 (4)
- December 2020 (3)
- November 2020 (5)
- October 2020 (4)
- September 2020 (3)
- August 2020 (3)
- July 2020 (6)
- June 2020 (4)
- May 2020 (4)
- April 2020 (3)
- March 2020 (6)
- February 2020 (3)
- January 2020 (4)
- December 2019 (5)
- November 2019 (4)
- October 2019 (2)
- September 2019 (4)
- August 2019 (4)
- July 2019 (3)
- June 2019 (7)
- May 2019 (6)
- April 2019 (5)
- March 2019 (6)
- February 2019 (5)
- January 2019 (8)
- December 2018 (3)
- November 2018 (4)
- October 2018 (7)
- September 2018 (6)
- August 2018 (5)
- July 2018 (8)
- June 2018 (6)
- May 2018 (5)
- April 2018 (6)
- March 2018 (4)
- February 2018 (6)
- January 2018 (4)
- December 2017 (2)
- November 2017 (3)
- October 2017 (2)
- September 2017 (4)
- August 2017 (2)
- July 2017 (4)
- June 2017 (5)
- May 2017 (6)
- April 2017 (6)
- March 2017 (5)
- February 2017 (4)
- January 2017 (1)
- July 2016 (3)
- May 2016 (1)
- April 2016 (2)
No Comments Yet
Let us know what you think